Form 4: Guardant Health Director's RSU Vesting Reported

Guardant Health Director Steve Krognes reported the vesting of 155 restricted stock units into common stock on August 31, 2025.

Summary

• Director Steve Krognes reported a change in beneficial ownership of Guardant Health, Inc. common stock.
• On August 31, 2025, 155 restricted stock units (RSUs) vested and converted into 155 shares of common stock.
• The RSUs were part of an award granted on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting monthly over three years from June 30, 2023.
• Following this transaction, Krognes directly owns 18,128 shares of common stock and 1,543 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled vesting of restricted stock units for a director, which is a standard compensation event and does not indicate any significant positive or negative operational or financial news.

Positives

• Director Steve Krognes continues to hold a significant number of common shares (18,128) and restricted stock units (1,543), indicating continued alignment with shareholder interests.

Future Outlook

The filing details a future vesting event on August 31, 2025, as part of a pre-existing RSU grant schedule, indicating an ongoing compensation structure for the director. The remaining 1,543 RSUs will continue to vest according to the established monthly schedule.

Industry Context

This is a standard insider transaction report, common across all publicly traded companies. It reflects a director's compensation structure, which often includes equity awards like RSUs to align interests with shareholders.

Comparison to Industry Standards

• Equity-based compensation, including Restricted Stock Units (RSUs), is a common practice for directors and executives in the biotechnology and healthcare industry, similar to companies like Illumina (ILMN) or Exact Sciences (EXAS).
• The multi-year vesting schedule for RSUs is a standard mechanism to incentivize long-term performance and align director interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The vesting increases the director's direct ownership, potentially aligning interests further. It also represents a minor dilution from new shares issued, though this is standard for equity compensation.

Next Steps

• Future monthly vesting of the remaining 1,543 Restricted Stock Units for Steve Krognes as per the established three-year schedule from June 30, 2023.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting of restricted stock units for a director, which is a standard component of executive compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining the current investment stance based on broader company fundamentals rather than this specific insider transaction.

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Compensation, Steve Krognes, Beneficial Ownership